Additional studies examining both tamoxifen and aromatase inhibitors have also found that either vasomotor, musculoskeletal, or joint symptoms may be associated with improved breast cancer outcomes23,24 but results have been mixed29,30. This evidence concerns the gene CYP19A1 and breast carcinoma.